Engineered Proteins Pull Double Duty

An efficient chemical approach to bispecific antibodies and antibodies of high valency

(2009) Julia I. Gavrilyuk et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Engineering and characterization of a bispecific HER2 × EGFR-binding affibody molecule

(2009) Mikaela Friedman et al.   BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY

Bispecific T-Cell Engaging Antibodies for Cancer Therapy

(2009) P. A. Baeuerle et al.   CANCER RESEARCH

The Design and Characterization of Oligospecific Antibodies for Simultaneous Targeting of Multiple Disease Mediators

(2009) Nazzareno Dimasi et al.   JOURNAL OF MOLECULAR BIOLOGY

DARPins as Bispecific Receptor Antagonists Analyzed for Immunoglobulin E Receptor Blockage

(2009) Alexander Eggel et al.   JOURNAL OF MOLECULAR BIOLOGY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis

(2009) T. Ben-Kasus et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

(2009) J. Bostrom et al.   SCIENCE

Complement-Dependent Tumor Cell Lysis Triggered by Combinations of Epidermal Growth Factor Receptor Antibodies

(2008) M. Dechant et al.   CANCER RESEARCH

A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer

(2008) J. Randolph Hecht et al.   JOURNAL OF CLINICAL ONCOLOGY

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Developing therapeutic proteins by engineering ligand–receptor interactions

(2008) Douglas S. Jones et al.   TRENDS IN BIOTECHNOLOGY